Sarepta Therapeutics
Update in progressSRPT (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, siRNA platforms, gene therapy, and other genetic approaches for rare diseases. Its Duchenne programs include Exondys 51, Vyondys 53, and Amondys 45 for exon-skipping mutations, and Elevidys, an AAV gene therapy with exon-8/9 deletion contraindications. It also develops SRP-9003 for LGMD2E, SRP-1001 (DUX4 knockdown), and SRP-1003 (DMPK reduction). The company collaborates with Roche, Arrowhead, UWA, Nationwide Children’s, Hansa, and Duke. Founded 1980, based in Cambridge, MA.
Company score
- Sentiment
- -0.57
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.90
- Governance
- -0.69
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.41
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.49
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!